COMMUNIQUÉS West-GlobeNewswire

MITHRA COMPLETES RECRUITMENT FOR ESTELLE® PHASE III STUDY IN US & CANADA
30/10/2017
PRESS RELEASE MITHRA COMPLETES RECRUITMENT FOR estelle® phase iii study in US & Canada Estelle ® Phase III study in US/Canada remains on track to report top line data in Q1 2019 Study recruited 2148 women in total; [...]
ESPERITE (ESP) : L1 Capital subscribes to the Ninth tranche of investment today
30/10/2017
Amsterdam, The Netherlands - 30 October 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the Ninth Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]
Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA
30/10/2017
Long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting[1],[2] Structural disease progression is a major concern for AS and [...]
Glycotope: Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing
30/10/2017
Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing Tokyo, Japan, Basking Ridge, NJ, and Berlin, Germany - (October 30, 2017) - Daiichi Sankyo Company [...]
MDxhealth Enters into Distribution Agreement with Unilabs for SelectMDx for Prostate Cancer
30/10/2017
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, October 30, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that the company has entered into an agency [...]
MDxHealth a conclu un contrat de distribution avec Unilabs pour le test de détection du cancer de la prostate SelectMDx
30/10/2017
COMMUNIQUÉ DE PRESSE / INFORMATION REGLEMENTAIRE / INFORMATION PRIVILEGIEE IRVINE, CA, et HERSTAL, BELGIQUE - 07:00 CEST, 30 octobre 2017 - MDxHealth SA (Euronext : MDXH.BR) a annoncé aujourd'hui que l'entreprise avait [...]
argenx launches Phase I trial with subcutaneous formulation of ARGX-113
30/10/2017
Subcutaneous formulation intended for chronic therapy setting October 30, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep [...]
CapsoVision annonce l'obtention du marquage CE pour l'utilisation de sa vidéo-capsule CapsoCam Plus chez les patients âgés de 2 ans et plus
30/10/2017
La technologie disruptive de CapsoCam Plus offre des images latérales panoramiques de 360º et leur enregistrement dans la capsule, éliminant ainsi le recours à des équipements externes. SARATOGA, Californie, le 25 [...]
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
30/10/2017
Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation Acquisition would add Lutathera ® , a first-in-class RadioLigand Therapy (RLT) approved in Europe and [...]
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a
28/10/2017
PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a Currently there are no specifically approved disease modifying therapies for children and [...]
ABLYNX CLOSES $200 MILLION INITIAL PUBLIC OFFERING IN THE UNITED STATES
27/10/2017
REGULATED INFORMATION GHENT, Belgium, 27 October 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] , a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments [...]
uniQure Announces Closing of its Public Offering
27/10/2017
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 27, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical [...]
UPDATE -- CapsoVision, Inc. Announces CE Mark for the Use of CapsoCam Plus Capsule Endoscopy System in Patients Ages 2 and Above*
27/10/2017
Award-winning technology provides 360º imaging, eliminates need for receiver equipment during examination SARATOGA, Calif., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Today Silicon Valley-based CapsoVision, Inc. announced CE [...]
NEOVACS : RÉSULTATS SEMESTRIELS 2017 ET POINT SUR LES AVANCÉES OPÉRATIONNELLES
27/10/2017
COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE RÉSULTATS SEMESTRIELS 2017 ET POINT SUR LES AVANCÉES OPÉRATIONNELLES FIN DU RECRUTEMENT DES PATIENTS DANS L'ÉTUDE CLINIQUE DE PHASE IIb AVEC l'IFNalpha [...]
NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS
27/10/2017
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS COMPLETED PATIENT ENROLLMENT IN PHASE IIb CLINICAL STUDY OF IFNalpha KINOID FOR TREATMENT OF [...]
Shire plc : 3rd Quarter Results
27/10/2017
Shire reports strong earnings growth in Q3 2017; reiterates full year guidance Product sales increased 7%, mainly driven by rapid growth in Immunology franchise Generated $1.1 billion operating cash flow; remain on- [...]
Preferred Dental Technologies Inc. ("Company") (CSE: PDT): Addresses the growing digital dentistry market
27/10/2017
Prototypes for EAS have been successfully created in multiple materials WINNIPEG, Manitoba, Oct. 27, 2017 (GLOBE NEWSWIRE) -- PDT's Evolutionary Accessory Series (EAS) is used to create custom dental abutments for the [...]
Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
27/10/2017
Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of oncology medicine filgrastim [...]
Targovax ASA: Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units
27/10/2017
The board of directors of Targovax ASA (the "Company") has on 27 October 2017, in accordance with the authorisations granted by the general meeting on 5 April 2017, resolved: - to increase the share capital of up to NOK [...]

Pages